NCT06076291View on ClinicalTrials.gov

An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

September 27, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Advanced Solid Tumors
Interventions
DRUG

SG1827

PhaseⅠa will use an accelerated titration and Bayesian optimal interval (AT-BOIN) design with 7 dose cohorts: 0.02mg/kg, 0.2mg/kg, 1mg/kg, 3mg/kg, 6mg/kg, 10mg/kg, and 15mg/kg by IV infusion. Accelerated titration (1 patient) will be only applied to the first cohort.

Trial Locations (6)

100021

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

110002

The First Hospital of China Medical University, Shenyang

230001

The Affiliated Hospital of USTC, Hefei

310003

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

410013

The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha

450003

Henan Cancer Hospital, Zhenzhou

All Listed Sponsors
lead

Hangzhou Sumgen Biotech Co., Ltd.

INDUSTRY